SCHEMBL12215182

SCHEMBL12215182

COc1ccc(C#N)c2[nH]cc(C(=O)C(=O)O)c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ USP2 O75604 1/20 0.40
▸ HPGD P15428 1/20 0.39
▸ MAP3K5 Q99683 1/20 0.38
▸ PRKAB2 O43741 1/20 0.38
▸ PRKAG1 P54619 1/20 0.38
▸ PRKAA2 P54646 1/20 0.38
▸ PRKAA1 Q13131 1/20 0.38
▸ PRKAG3 Q9UGI9 1/20 0.38
▸ PRKAG2 Q9UGJ0 1/20 0.38
▸ PRKAB1 Q9Y478 1/20 0.38
▸ IMPDH2 P12268 1/20 0.37
▸ IMPDH1 P20839 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CNR1 P21554 1/20 0.36
▸ CNR2 P34972 1/20 0.36
▸ F11 P03951 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12215433 0.90 ALDH1A1 (0.43) ALDH1A1KDM4EUSP2HPGDMAP3K5
SCHEMBL12513804 0.81 KDM4E (0.42) ALDH1A1KDM4EHPGDPRKAB2PRKAG1
SCHEMBL2629105 0.77 CYP2C9 (0.44) ALDH1A1KDM4EHPGDMAP3K5PRKAB2
Water SCHEMBL1733706 0.72 CYP2C9 (0.60) ALDH1A1KDM4EHPGDCYP2C9CNR1
SCHEMBL12215333 0.71 KDM4E (0.47) ALDH1A1KDM4EHPGDPRKAB2PRKAG1
SCHEMBL10326256 0.70 CYP2C9 (0.47) ALDH1A1KDM4EHPGDCYP2C9CNR1
SCHEMBL12238398 0.70 CYP2C9 (0.47) ALDH1A1KDM4EHPGDCYP2C9CNR1
SCHEMBL1472698 0.70 CYP2C9 (0.61) ALDH1A1KDM4EHPGDCYP2C9CNR1
SCHEMBL1550197 0.69 CYP2C9 (0.47) ALDH1A1KDM4EHPGDCYP2C9CNR1
SCHEMBL2628952 0.69 CYP2C9 (0.47) ALDH1A1KDM4EHPGDPRKAB2PRKAG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8039486-B2 Viricides, immunomodulators or HIV entry inhibitors; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-10-18 — — US disclosed
US-8039486-B2 Viricides, immunomodulators or HIV entry inhibitors; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-10-18 — — US disclosed
US-20080132516-A1 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY 2008-06-05 — — US disclosed
US-20080132516-A1 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY 2008-06-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132516-A1 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES IDO2, IDO1, INMT ALDH1A1 2529/4885KDM4E 709/4885USP2 2397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback